Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z.

Mod Pathol. 2011 Jul;24(7):899-907. doi: 10.1038/modpathol.2011.47. Epub 2011 Apr 1.

2.

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Langer R, Rauser S, Feith M, Nährig JM, Feuchtinger A, Friess H, Höfler H, Walch A.

Mod Pathol. 2011 Jul;24(7):908-16. doi: 10.1038/modpathol.2011.52. Epub 2011 Apr 22.

3.

Early HER2 dysregulation in gastric and oesophageal carcinogenesis.

Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M.

Histopathology. 2012 Nov;61(5):769-76. doi: 10.1111/j.1365-2559.2012.04272.x. Epub 2012 Aug 9.

PMID:
22882541
4.

Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.

Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR.

Ann Surg Oncol. 2011 Jul;18(7):2010-7. doi: 10.1245/s10434-011-1554-1. Epub 2011 Jan 26.

PMID:
21267790
5.

Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.

Zhou Z, Bandla S, Ye J, Xia Y, Que J, Luketich JD, Pennathur A, Peters JH, Tan D, Godfrey TE.

BMC Gastroenterol. 2014 Apr 17;14:78. doi: 10.1186/1471-230X-14-78.

6.

Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.

Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL.

Med Oncol. 2012 Jun;29(2):933-40. doi: 10.1007/s12032-011-9850-y. Epub 2011 Feb 13.

PMID:
21318736
7.
8.

TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.

Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R.

Histopathology. 2010 Jul;57(1):81-9. doi: 10.1111/j.1365-2559.2010.03580.x. Epub 2010 Jun 16.

9.

HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.

Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA.

Cancer. 2014 Feb 1;120(3):415-24. doi: 10.1002/cncr.28435. Epub 2013 Oct 21.

10.

Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5. doi: 10.1158/1055-9965.EPI-07-2734.

11.
12.

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G.

Mod Pathol. 2007 Jan;20(1):120-9. Epub 2006 Nov 24.

13.

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.

Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA.

Clin Cancer Res. 2012 Jan 15;18(2):546-54. doi: 10.1158/1078-0432.CCR-11-2272.

15.

The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.

Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti D, Zaninotto G, Rugge M.

Hum Pathol. 2013 Sep;44(9):1804-10. doi: 10.1016/j.humpath.2013.01.023. Epub 2013 Apr 22.

PMID:
23618359
16.

The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.

Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ.

Ann Oncol. 2013 May;24(5):1290-7. doi: 10.1093/annonc/mds640. Epub 2013 Jan 18.

17.

Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M, Aubele M, Stein H, Siewert JR, Höfler H, Werner M.

Lab Invest. 2001 Jun;81(6):791-801.

PMID:
11406641
18.

Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.

König AM, Reeh M, Dancau AM, Rathjens M, Gros S, Uzunoglu FG, Bockhorn M, Simon R, Sauter G, Marx A, Izbicki JR.

Anticancer Res. 2013 Nov;33(11):4975-82.

PMID:
24222138
19.

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.

Hum Pathol. 2012 Mar;43(3):413-22. doi: 10.1016/j.humpath.2011.05.019. Epub 2011 Aug 19.

PMID:
21855114
20.

HER2/CHR 17 tissue microarray chromogenic in situ hybridization analysis in colon adenocarcinoma: multiple gene signals vs protein expression.

Fotiades PP, Tsiambas E, Lazaris AC, Saetta AA, Karameris A, Vilaras G, Patsouris E.

J BUON. 2014 Jan-Mar;19(1):109-14.

PMID:
24659651
Items per page

Supplemental Content

Write to the Help Desk